Floatz logo

Irinotecan

Solid Carcinoma

Institut de Recherches Internationales ServierSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Solid Carcinoma cohort.

Asset / SponsorPhaseRating
[18f]f-resca-rt4
RenJi Hospital
Phase 2/3CCC
[18F]F-RESCA-T4
RenJi Hospital
Phase 2/3CCC
[68ga]ga-nota-t4
RenJi Hospital
Phase 2/3CCC
Nivolumab
Asan Medical Center
Phase 1/2CCC
[68ga]ga-nota-rt4
RenJi Hospital
Phase 2/3CCC

View all 44 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →